disopyramide has been researched along with sotalol in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.12) | 18.7374 |
| 1990's | 11 (33.33) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 8 (24.24) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baizman, ER; Becker, C; Bell, RH; Birsner, NC; Bohnet, EA; Busacca, CA; Carabateas, PM; Chadwick, CC; Gruett, MD; Johnson, RE | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Garthwaite, SM; Hackett, AM; McDonald, SJ; Schneider, P; Schweingruber, F | 1 |
| Camm, AJ; Garratt, CJ; Griffith, MJ; Linker, NJ; Ward, DE | 1 |
| Hoffman, BF; Spinelli, W | 1 |
| Huang, SK; Marcus, FI | 1 |
| Gomoll, AW | 1 |
| Campbell, TJ; Gavaghan, TP; Morgan, JJ | 1 |
| Carlsson, B; Drvota, V; Häggblad, J; Sylvén, C | 1 |
| Campbell, TJ; Wyse, KR; Ye, V | 1 |
| Bystedt, T; Vitols, S | 1 |
| Lüderitz, B; Manz, M | 1 |
| Fromm, BS; Lehmann, MH; Makkar, RR; Meissner, MD; Steinman, RT | 1 |
| Brechenmacher, C; Chauvin, M; Koenig, A; Theolade, R | 1 |
| Bursill, JA; Campbell, TJ; Wyse, KR | 1 |
| Crijns, HJ; Panhuyzen-Goedkoop, NM | 1 |
| Morozova, OI; Pozdniakova, NV; Shevyrev, VA; Tatarchenko, IP | 1 |
| Mounsey, JP; VerNooy, RA | 1 |
| Scharf, C | 1 |
7 review(s) available for disopyramide and sotalol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiarrhythmic drug therapy of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Tosylate; Disopyramide; Flecainide; Heart Ventricles; Humans; Lidocaine; Mexiletine; Moricizine; Phenothiazines; Phenytoin; Piperidines; Procainamide; Propafenone; Propiophenones; Quinidine; Sotalol; Tocainide; Verapamil | 1986 |
Supraventricular tachycardia and pre-excitation syndromes: pharmacological therapy.
Topics: Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Disopyramide; Flecainide; Humans; Imidazoles; Pre-Excitation Syndromes; Propafenone; Quinidine; Sotalol; Tachycardia, Paroxysmal; Tachycardia, Supraventricular; Verapamil | 1993 |
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Bepridil; Cardiovascular Agents; Disopyramide; Female; Humans; Male; Middle Aged; Prenylamine; Procainamide; Quinidine; Risk Factors; Sex; Sotalol; Syncope; Tachycardia, Ventricular; Torsades de Pointes | 1993 |
[Antiarrhythmic treatment after reduction of atrial fibrillation by external shock].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Disopyramide; Electric Countershock; Flecainide; Humans; Propafenone; Quinidine; Recurrence; Sotalol | 1993 |
Antiarrhythmic drug therapy of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Flecainide; Humans; Phenethylamines; Sotalol; Sulfonamides | 2004 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Calcium Channel Blockers; Catheter Ablation; Clinical Trials as Topic; Disopyramide; Electric Countershock; Electrocardiography; Emergencies; Flecainide; Heart Rate; Humans; Middle Aged; Pacemaker, Artificial; Propafenone; Quinidine; Recurrence; Sotalol; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2005 |
2 trial(s) available for disopyramide and sotalol
| Article | Year |
|---|---|
Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia.
Topics: Adenosine; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Clinical Trials as Topic; Disopyramide; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Electric Countershock; Electrocardiography; Flecainide; Humans; Hypotension; Injections, Intravenous; Lidocaine; Middle Aged; Recurrence; Sotalol; Tachycardia | 1990 |
Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial.
Topics: Atrial Fibrillation; Atrial Flutter; Cardiopulmonary Bypass; Clinical Trials as Topic; Digoxin; Disopyramide; Female; Humans; Infusions, Parenteral; Injections, Intravenous; Male; Middle Aged; Postoperative Complications; Sotalol | 1985 |
24 other study(ies) available for disopyramide and sotalol
| Article | Year |
|---|---|
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepines; Cats; Disease Models, Animal; Dogs; Guinea Pigs; Heart Ventricles; Male; Myocardial Contraction; Myocardial Infarction; Potassium Channels; Rats; Rats, Sprague-Dawley; Refractory Period, Electrophysiological; Sodium Channels; Structure-Activity Relationship | 1993 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Simple in vitro method to characterize antiarrhythmic agents.
Topics: Acecainide; Animals; Anti-Arrhythmia Agents; Disopyramide; Electric Stimulation; Guinea Pigs; In Vitro Techniques; Myocardial Contraction; Papillary Muscles; Quaternary Ammonium Compounds; Refractory Period, Electrophysiological; Sotalol; Verapamil | 1990 |
Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Disopyramide; Dogs; Electrocardiography; Flecainide; Heart Conduction System; Heart Rate; Lidocaine; Piperidines; Propafenone; Sotalol | 1989 |
Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electrocardiography; Encainide; Female; Flecainide; Male; Myocardial Infarction; Sotalol | 1987 |
Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype beta 1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect.
Topics: Amiodarone; Anti-Arrhythmia Agents; Binding, Competitive; Disopyramide; Dose-Response Relationship, Drug; Humans; Lidocaine; Metoprolol; Propafenone; Receptors, Thyroid Hormone; Sotalol; Triiodothyronine; Verapamil | 1995 |
Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: implications for proarrhythmia due to triggered activity.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Cesium; Disopyramide; Dogs; Dose-Response Relationship, Drug; In Vitro Techniques; Microelectrodes; Purkinje Fibers; Quinidine; Sotalol | 1993 |
[A case report. Sotalol-disopyramide caused asystole].
Topics: Administration, Oral; Aged; Disopyramide; Drug Interactions; Heart Arrest; Humans; Infusions, Intravenous; Male; Sotalol | 1994 |
Differential effects of antiarrhythmic agents on post-pause repolarization in cardiac Purkinje fibres.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Amitriptyline; Animals; Anti-Arrhythmia Agents; Disopyramide; Dogs; Dose-Response Relationship, Drug; Phenethylamines; Potassium Channels; Purkinje Fibers; Quaternary Ammonium Compounds; Quinidine; Sodium Channels; Sotalol; Sulfonamides | 1996 |
[Iatrogenic collapse; can this be prevented?].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Disopyramide; Erythromycin; Female; Humans; Long QT Syndrome; Male; Middle Aged; Sotalol; Syncope | 1997 |
[Anti-arrhythmic therapy: diagnostic possibilities of signal-averaged electrocardiography and heart rate variability].
Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Data Interpretation, Statistical; Disopyramide; Electrocardiography; Electrocardiography, Ambulatory; Female; Heart; Heart Rate; Humans; Male; Middle Aged; Phenothiazines; Sotalol | 2003 |
Atrial fibrillation: rate control often better than rhythm control.
Topics: Adult; Aged; Amiodarone; Anticoagulants; Arrhythmia, Sinus; Atrial Fibrillation; Canada; Disopyramide; Electric Countershock; Flecainide; Heart Rate; Humans; Netherlands; Platelet Aggregation Inhibitors; Propafenone; Quinidine; Sotalol; United States | 2004 |